Skip to main content
SpringerLink
Log in

Adding neprilysin inhibitors to ACE inhibitors or ARBs does not increase renal adverse events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis

Reference

  • Barbosa CV, et al. Renal events in patients receiving Neprilysin inhibitors: a systematic review and meta-analysis. Nephrology Dialysis Transplantation : 11 Jan 2022. Available from: URL: http://doi.org/10.1093/ndt/gfac001

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adding neprilysin inhibitors to ACE inhibitors or ARBs does not increase renal adverse events. Reactions Weekly 1891, 3 (2022). https://doi.org/10.1007/s40278-022-09255-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-09255-7

Search

Navigation